Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Cereblon (CRBN) Target Engagement from US Patent US20240246935: "ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2"
Assay data:69 Active, 68 Activity ≤ 1 µM, 84 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Lenalidomide Assay from US Patent US12030892: "CRBN modulators"
Assay data:3 Active, 2 Activity ≤ 1 µM, 3 Tested
HTRF (Homogeneous Time-Resolved Fluorescence) Assay from US Patent US20240207267: "(R)-Glutarimide CRBN Ligands and Methods of Use"
Assay data:9 Active, 8 Activity ≤ 1 µM, 9 Tested
CDK9/CyclinT1 Kinase Inhibitory Activity Assay from US Patent US20240166635: "AMINOHETEROARYL KINASE INHIBITORS"
Assay data:143 Active, 156 Activity ≤ 1 µM, 156 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by DepositorRelated BioAssays by Target
CDK Inhibition In Vitro Assay from US Patent US20240150369: "CYCLIN-DEPENDENT KINASE INHIBITING COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS"
Assay data:31 Active, 8 Activity ≤ 1 nM, 31 Activity ≤ 1 µM, 31 Tested
In Vitro Enzymatic Inhibitory Activity Assay from US Patent US20240132489: "AROMATIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF"
Assay data:55 Active, 55 Activity ≤ 1 µM, 55 Tested
CRBN Fluorescence Polarization Assay from US Patent US20240132463: "SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGS AS MODULATORS OF CEREBLON PROTEIN"
Assay data:5 Active, 5 Activity ≤ 1 µM, 5 Tested
Activity Inhibition Assay on CDK Family Kinases from US Patent US20240109898: "SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE DERIVATIVES, COMPOSITIONS AND PHARMACEUTICAL USES THEREOF"
Assay data:84 Active, 83 Activity ≤ 1 µM, 84 Tested
Cereblon Binding Assay from US Patent US20240109877: "PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE"
Assay data:14 Active, 5 Activity ≤ 1 µM, 19 Tested
Compound Activity by Fluorescent Polarization Assay from US Patent US11912682: "Isoindolinone compounds"
Assay data:126 Active, 103 Activity ≤ 1 µM, 155 Tested
Cereblon Binding Assay from US Patent US20240059711: "Cereblon Ligands and Uses Thereof"
Assay data:15 Active, 10 Activity ≤ 1 µM, 15 Tested
Cereblon Binding Assay from US Patent US20240059704: "Cereblon Ligands and Uses Thereof"
Assay data:5 Active, 2 Activity ≤ 1 µM, 5 Tested
In Vitro Assay: IC50 Measurements for Binding to CRBN/DDB1 from US Patent US20240059704: "Cereblon Ligands and Uses Thereof"
Assay data:4 Active, 1 Activity ≤ 1 µM, 4 Tested
Fluorescent Polarization Assay from US Patent US20240051936: "ISOINDOLINONE COMPOUNDS"
Assay data:40 Active, 30 Activity ≤ 1 µM, 66 Tested
Inhibition of C-terminal His6 tagged full length recombinant human CDK9/full length human Cyclin T1 expressed in baculovirus infected Sf21 cells using 5-FAM-ACSYSPTSPSYSPTSPSYSPTSPSKK as substrate at 10 uM incubated for 60 mins in presence of ATP relative to control
Assay data:1 Tested
SummaryPubMed CitationRelated BioAssays by Target
Inhibition of C-terminal His6 tagged full length recombinant human CDK9/full length human Cyclin T1 expressed in baculovirus infected Sf21 cells using 5-FAM-ACSYSPTSPSYSPTSPSYSPTSPSKK as substrate incubated for 60 mins in presence of ATP
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Protac activity at CRBN/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 10 uM incubated for 6 hrs by Western blot analysis (Rvb = 0%)
Assay data:2 Tested
Protac activity at CRBN/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 1 uM incubated for 6 hrs by Western blot analysis (Rvb = 0%)
Protac activity at CRBN/AR in AR-positive human LNCaP cells assessed as induction of androgen receptor degradation at 0.1 uM incubated for 6 hrs by Western blot analysis (Rvb = 0%)
PROTAC activity at CRBN/BRD7 in human Ri-1 cells assessed as remaining BRD7 protein level at 1 uM incubated for 8 hrs by Western blot analysis relative to control
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on